It is no exaggeration to say that since early 2020, the world has radically changed because of the pandemic caused by the novel coronavirus, also known as COVID-19. Drastic preventative measures including social distancing have overshadowed our day-to-day dynamics. An urgent quest has ensued to find effective strategies against COVID-19 by using traditional and novel pharmacotherapy and developing vaccines if possible. Because COVID-19 virus invades human cells through the angiotensin-converting enzyme 2 (ACE2) receptors, heated discussions abound as to whether prior use of ACE inhibitors or angiotensin receptor blockers (ARB) can cause ACE2 receptor upregulation that would in turn lead to worse COVID-19 infection.